Daily Bio News Summary — 2026-06-30

The biopharma news cycle on 2026-06-30 was dominated by regulatory activity at the FDA (nine press announcements spanning approvals, CRLs, and program launches) and a dense slate of clinical and corporate-development headlines across the trade press. Twenty fresh news files were written in this run, drawn from BioSpace, Fierce Pharma, FDA Newsroom, and STAT News; Endpoints News is currently behind a soft paywall and was excluded pending replacement-source verification per the cron’s Rule 8.

FDA program launches and approvals (FDA Newsroom)

The FDA published nine press announcements within the 30-day window, including the agency-backed PreCheck Pilot Program (an incentive program for U.S. drug manufacturing that selected seven participants — Eli Lilly, Regeneron, and five others). Other FDA actions ranged from the first over-the-counter continuous glucose monitor for children, an expanded OTC naloxone nasal spray for opioid overdose, and an emergency use authorization for a generic OTC treatment of New World screwworm in companion animals. The agency also approved the first single-dose generic treatment for influenza and issued draft guidance to accelerate cell and gene therapies. Two approvals within this batch (the PreCheck Pilot and the OTC naloxone) are likely to receive follow-on coverage from the trade press in the days ahead.

Manufacturing CRLs for Sobi and Unicycive (Fierce Pharma / BioSpace)

Two of the day’s most-cited clinical stories were CRLs for Sobi’s gout combination therapy and Unicycive’s kidney drug (oxylanthanum carbonate) — both citing contract-manufacturing deficiencies. The BioSpace writeup framed both rejections as a single FDA enforcement action, while Fierce Pharma covered the Sobi and Unicycive stories separately. The cron’s Tier 2 dedupe kept the BioSpace version (higher canonical-source priority) and dropped the Fierce Pharma duplicate.

Therapeutics development pipeline (Fierce Pharma / BioSpace)

• AbbVie / Genmab’s Epkinly (epcoritamab) showed a Phase 3 progression-free survival benefit in DLBCL in combination with rituximab and lenalidomide, redeeming the bispecific after its earlier monotherapy failure.
• BeOne Medicines’ Brukinsa (zanubrutinib) hit its primary endpoint in a mantle cell lymphoma confirmatory trial.
• Viridian Therapeutics’ Lumvoa (veligrotug) received FDA approval for thyroid eye disease, setting up direct competition with Amgen’s Tepezza.
• Evommune discontinued its lead chronic-spontaneous-urticaria candidate after a mid-stage efficacy failure.
• Praxis Precision Medicines’ relutrigine was hit with a three-month FDA delay for its epilepsy drug PDUFA.

Business and strategy

Zymeworks agreed to acquire Theravance Biopharma for $929 million, taking out the struggling respiratory-focused specialty pharma after a Phase 3 failure of its lead asset. Klick Health acquired UK-based medical communications firm Oxford PharmaGenesis, the agency’s third takeover in 18 months. Deerfield Management’s Boulevard Bio struck a deal worth up to $1.6 billion with China’s Metis TechBio for a trispecific T-cell engager in autoimmune disease.

STAT News

STAT published a five-takeaways piece summarizing its investigation into microhospital operator Nutex Health, focused on No Surprises Act billing practices and hospital-acquisition patterns.

What this batch is NOT telling us

• AI-in-bio is absent from this run’s curated output. Recent AI-bio coverage was limited or behind paywalled destinations.
• Endpoints News is excluded because of its mid-2026 soft paywall (“Sign up to read this article for free” / “BECOME A PREMIUM SUBSCRIBER”). The 35 Endpoints candidates from today’s homepage parse were filtered per the cron’s paywall verification (Rule 8); finding replacement sources for the headline stories is a follow-up task.
• No clinical-stage AI drug design news surfaced in today’s parse; the typical Recursion / Insilico / Isomorphic / Generate churn was not represented.

Reading order (highest-signal first)

1. Viridian set for 1-on-1 vs. Amgen after FDA approval of Lumvoa — direct competition with a blockbuster in TED.
2. FDA Selects Seven Participants for PreCheck Pilot Program to Advance U.S. Drug Manufacturing — the day’s most strategically significant regulatory action.
3. After trial fail, Teravance is bought out by Zymeworks for $929M — a clean read-through on respiratory-pipeline economics.
4. AbbVie, Genmab’s Epkinly redeems itself in DLBCL — Phase 3 combo data restores a high-profile bispecific.
5. BeOne’s Brukinsa hits goal in lymphoma confirmatory trial — supportive data for an already-marketed asset.

How to read the underlying articles

Each of the 20 items below is a separate markdown file under src/content/news/ in the openbionews.com repository. The sourceUrl field on each frontmatter is the canonical link to the underlying trade-press article. The companyId field (where present) links the news item to the corresponding company profile in src/content/companies/.

Today’s harvest — full item list

1. Lilly, Regeneron among 7 chosen for FDA PreCheck Pilot Program (Fierce Pharma, 2026-06-30)
2. AbbVie, Genmab’s Epkinly redeems itself in DLBCL (Fierce Pharma, 2026-06-30)
3. Unicycive approval filing turned away by FDA again (Fierce Pharma, 2026-06-30)
4. BeOne’s Brukinsa hits goal in lymphoma confirmatory trial (Fierce Pharma, 2026-06-30)
5. Klick bags Oxford PharmaGenesis in 3rd takeover in 18 months (Fierce Pharma, 2026-06-30)
6. FDA’s cell and gene therapy head steps down after 1 year (BioSpace, 2026-06-30)
7. FDA rejects Unicycive and Sobi filings over contract manufacturing deficiencies (BioSpace, 2026-06-30)
8. Deerfield bets up to $1.6B to snag autoimmune asset in China for Boulevard (BioSpace, 2026-06-30)
9. Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes (BioSpace, 2026-06-30)
10. FDA hits Praxis with 3-month delay for epilepsy drug verdict (BioSpace, 2026-06-30)
11. Skyhawk CEO hopes FDA’s new uniQure position will translate to Huntington’s pill (BioSpace, 2026-06-30)
12. 5 takeaways from STAT’s investigation into microhospital operator Nutex Health (STAT News, 2026-06-29)
13. Viridian set for 1-on-1 vs. Amgen after FDA approval of Lumvoa (Fierce Pharma, 2026-06-29)
14. After trial fail, Teravance is bought out by Zymeworks for $929M (Fierce Pharma, 2026-06-29)
15. FDA Selects Seven Participants for PreCheck Pilot Program to Advance U.S. Drug Manufacturing (FDA Newsroom, 2026-06-29)
16. FDA Proposes Rule That Would Help Hold Foreign Tobacco Product Manufacturers Accountable, Protect Public Health (FDA Newsroom, 2026-06-26)
17. FDA Approves First Single-Dose Generic Treatment for Influenza (FDA Newsroom, 2026-06-17)
18. FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose (FDA Newsroom, 2026-06-16)
19. FDA Clears First Over-the-Counter Continuous Glucose Monitor for Children (FDA Newsroom, 2026-06-12)
20. FDA Issues Emergency Use Authorization for Generic Over-the-Counter Drug to Treat New World Screwworm in Dogs and Cats (FDA Newsroom, 2026-06-11)
21. FDA Expands Sunscreen Options for the First Time in 20 Years (FDA Newsroom, 2026-06-09)
22. FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients (FDA Newsroom, 2026-06-02)